Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion: 2013-2025

Historic Depreciation and Depletion for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $7.9 million.

  • Amphastar Pharmaceuticals' Depreciation and Depletion rose 8.85% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year increase of 11.56%. This contributed to the annual value of $28.2 million for FY2024, which is 12.08% up from last year.
  • Amphastar Pharmaceuticals' Depreciation and Depletion amounted to $7.9 million in Q3 2025, which was down 5.83% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Depreciation and Depletion registered a high of $8.3 million during Q2 2025, and its lowest value of $5.4 million during Q3 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Depreciation and Depletion had a median value of $7.0 million in 2024 and averaged $7.0 million.
  • Over the last 5 years, Amphastar Pharmaceuticals' Depreciation and Depletion had its largest YoY gain of 20.57% in 2021, and its largest YoY loss of 2.77% in 2021.
  • Amphastar Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $5.4 million in 2021, then climbed by 14.81% to $6.2 million in 2022, then rose by 7.19% to $6.6 million in 2023, then grew by 9.19% to $7.3 million in 2024, then increased by 8.85% to $7.9 million in 2025.
  • Its Depreciation and Depletion stands at $7.9 million for Q3 2025, versus $8.3 million for Q2 2025 and $7.4 million for Q1 2025.